Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the ...

WESTON, Mass.--(BUSINESS WIRE)--Oct. 4, 2013-- Data presented today show that TECFIDERA® (dimethyl fumarate) continues to offer consistent and strong efficacy combined with a favorable safety profile ...

CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data to support the consistent, long-term benefits of treatment with TECFIDERA® (dimethyl fumarate) over ...

TECFIDERA (dimethyl fumarate) 120mg and 240mg delayed-release caps by Biogen Idec Biogen presented new data at ECTRIMS showing that Tecfidera (dimethyl fumarate) significantly reduced multiple ...

CHMP Issues Positive Opinion for TECFIDERA™ (Dimethyl Fumarate) as a First-Line Treatment for Multiple Sclerosis in the European Union WESTON, Mass.--Mar. 22, 2013-- Today Biogen Idec (NASDAQ: BIIB) ...

About TECFIDERA (dimethyl fumarate) TECFIDERA, a treatment for relapsing forms of multiple sclerosis (MS) in adults, is the most prescribed oral medication for relapsing MS in the world and has been ...

A NEW oral drug for people with relapsing-remitting multiple sclerosis is to be made available in Scotland. Tecfidera (dimethyl fumarate) a first-line oral treatment could be an alternative to ...

CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that China’s National Medical Products Administration (NMPA) has approved TECFIDERA ® (dimethyl fumarate) ...

Biogen Idec to Begin Launching TECFIDERA in Initial EU Countries in the Coming Weeks CAMBRIDGE, Mass.--(BUSINESS WIRE)-- TECFIDERA® (dimethyl fumarate) has been approved by the European Commission (EC ...